A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study of Once-Weekly Tirzepatide Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
- Phone Number: 1-317-615-4559
- Email: ClinicalTrials.gov@lilly.com
Study Locations
-
-
California
-
Gardena, California, United States, 90247
- Velocity Clinical Research, Gardena
-
Irvine, California, United States, 92614
- Irvine Clinical Research
-
Los Angeles, California, United States, 90017
- Velocity Clinical Research, Los Angeles
-
North Hollywood, California, United States, 91606
- Velocity Clinical Research, North Hollywood
-
Santa Ana, California, United States, 92704
- Velocity Clinical Research, Santa Ana
-
Van Nuys, California, United States, 91405
- Velocity Clinical Research, Panorama City
-
Walnut Creek, California, United States, 94598
- Diablo Clinical Research, Inc.
-
-
Idaho
-
Meridian, Idaho, United States, 83646
- Solaris Clinical Research
-
-
Louisiana
-
Marrero, Louisiana, United States, 70072
- Tandem Clinical Research
-
New Orleans, Louisiana, United States, 70119
- Velocity Clinical Research - New Orleans
-
-
New Jersey
-
Marlton, New Jersey, United States, 08053
- Hassman Research Institute Marlton Site
-
-
North Dakota
-
Fargo, North Dakota, United States, 58104
- Lillestol Research
-
-
Ohio
-
Cincinnati, Ohio, United States, 45212
- CTI Clinical Research Center
-
-
Texas
-
Corpus Christi, Texas, United States, 78404
- South Texas Clinical Research
-
Dallas, Texas, United States, 75230
- Velocity Clinical Research, Dallas
-
Houston, Texas, United States, 77040
- Juno Research
-
-
Washington
-
Bellevue, Washington, United States, 98007
- Northwest Clinical Research Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Have a body mass index (BMI) of ≥30 kilogram/square meter (kg/m²) and ≤40 kg/m²
- Willing to learn how to self-inject study intervention (visually impaired persons who are not able to perform the injections must have the assistance of a sighted individual trained to inject the study intervention; persons with physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject the study intervention)
- Male or female contraceptive use by participant should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Exclusion Criteria:
- Have a history of diabetes mellitus, including Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM), history of ketoacidosis, or hyperosmolar state/coma
- Have a self-reported change (increase or decrease) in body weight >5 kilogram (kg) within 3 months prior to screening
- Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2
- Have acute or chronic hepatitis
- Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Tirzepatide (TZP) + Mibavademab (MIBA) [Group A]
Participants will receive TZP subcutaneously (SC) and MIBA for 24 weeks.
Participants in Group A will be randomized (Randomization 2) to groups C and D at week 24.
|
Administered SC
Other Names:
Administered SC
Other Names:
|
|
Experimental: TZP + Mibavademab-placebo (MIBA-PBO) [Group B]
Participants will receive TZP SC and MIBA-PBO SC for 24 weeks.
Participants in Group B will be randomized (Randomization 2) to Groups E, F, G, and H at week 24.
|
Administered SC
Other Names:
Administered SC
|
|
Experimental: TZP + MIBA then Tirzepatide-placebo (TZP-PBO) + MIBA [Group C]
Participants will receive TZP SC and MIBA SC for 24 weeks followed by TZP-PBO SC and MIBA SC for 24 weeks.
|
Administered SC
Other Names:
Administered SC
Other Names:
Administered SC
|
|
Experimental: TZP + MIBA-PBO [Group E]
Participants will receive TZP SC + MIBA-PBO SC for 48 weeks.
|
Administered SC
Other Names:
Administered SC
|
|
Experimental: TZP + MIBA-PBO then TZP-PBO + MIBA [Group F]
Participants will receive TZP SC + MIBA-PBO SC for 24 weeks followed by TZP-PBO SC + MIBA SC for 24 weeks.
|
Administered SC
Other Names:
Administered SC
Other Names:
Administered SC
Administered SC
|
|
Experimental: TZP + MIBA-PBO then TZP + MIBA [Group G]
Participants will receive TZP SC + MIBA-PBO SC for 24 weeks followed by TZP SC + MIBA SC for 24 weeks.
|
Administered SC
Other Names:
Administered SC
Other Names:
Administered SC
|
|
Experimental: TZP + MIBA-PBO then TZP-PBO + MIBA-PBO [Group H]
Participants will receive TZP SC + MIBA-PBO SC for 24 weeks followed by TZP-PBO SC + MIBA-PBO SC for 24 weeks.
|
Administered SC
Other Names:
Administered SC
Administered SC
|
|
Experimental: TZP + MIBA [Group D]
Participants will receive TZP SC + MIBA SC for 48 weeks.
|
Administered SC
Other Names:
Administered SC
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Mean Percent Change from Baseline in Body Weight
Time Frame: Baseline, Week 48
|
Baseline, Week 48
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of Participants Who Achieve ≥5% Body Weight Reduction
Time Frame: Baseline to Week 48
|
Baseline to Week 48
|
|
Percentage of Participants Who Achieve ≥10% Body Weight Reduction
Time Frame: Baseline to Week 48
|
Baseline to Week 48
|
|
Mean Change from Baseline for Percent Change and Absolute Change in Body Weight (kg)
Time Frame: Baseline, Week 24
|
Baseline, Week 24
|
|
Mean Absolute Change from Baseline for Body Weight (kg)
Time Frame: Baseline, Week 48
|
Baseline, Week 48
|
|
Percentage of Participants Who Achieve ≥15% Body Weight Reduction
Time Frame: Baseline to Week 48
|
Baseline to Week 48
|
|
Percentage of Participants Who Achieve ≥20 Body Weight Reduction
Time Frame: Baseline to Week 48
|
Baseline to Week 48
|
|
Mean Percent Change from Randomization 2 for Body Weight
Time Frame: Week 24, Week 48
|
Week 24, Week 48
|
|
Mean Change from Randomization 2 for Body Weight (kg)
Time Frame: Week 24, Week 48
|
Week 24, Week 48
|
|
Mean Absolute Change from Randomization 2 for Body Weight (kg)
Time Frame: Week 24, Week 48
|
Week 24, Week 48
|
|
Change from Baseline to Week 24 in CoEQ Scores
Time Frame: Baseline, Week 24
|
Baseline, Week 24
|
|
Change from Baseline in FCQ-T-r Scores
Time Frame: Baseline, Week 24
|
Baseline, Week 24
|
|
Change from Baseline in FCQ-T-r Scores
Time Frame: Baseline, Week 48
|
Baseline, Week 48
|
|
Change from Baseline to Week 48 in CoEQ Scores
Time Frame: Baseline, Week 48
|
Baseline, Week 48
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nutrition Disorders
- Overnutrition
- Body Weight
- Overweight
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Signs and Symptoms
- Obesity
- Amino Acids, Peptides, and Proteins
- Proteins
- Glucagon-Like Peptide-1 Receptor
- Glucagon-Like Peptide Receptors
- Receptors, G-Protein-Coupled
- Receptors, Cell Surface
- Membrane Proteins
- Receptors, Gastrointestinal Hormone
- Receptors, Peptide
- Tirzepatide
Other Study ID Numbers
Other Study ID Numbers
- 18750
- I8F-MC-GPIV (Other Identifier: Eli Lilly and Company)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.